INKON LIFE TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.5 CNY | -1.51% |
|
+2.78% | -20.04% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.48 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.04% | 746M | - | ||
| -18.90% | 16.51B | B+ | ||
| +4.50% | 12.53B | B | ||
| +4.81% | 11.74B | B+ | ||
| +2.43% | 10.06B | B+ | ||
| +29.69% | 8.71B | B | ||
| -4.75% | 7.57B | A- | ||
| +19.68% | 7.22B | D | ||
| +5.46% | 6.68B | B- | ||
| -2.79% | 4.32B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300143 Stock
- Ratings INKON Life Technology Co., Ltd.